We note that a slightly higher proportion of patients in our cohort with ES-TNBC (69%) completed all appropriate treatments compared to patients with LA-HR+/HER2- BC (66%), which potentially may impact clinical outcomes. This evidence concerns the gene ERBB2 and breast cancer.